Search
Ivarmacitinib
go.drugbank.com/drugs/DB16756InvestigationalWhile ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis … Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions.
Epoetin delta
go.drugbank.com/drugs/DB11624ApprovedWithdrawnEpoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
TC-5231
go.drugbank.com/drugs/DB05333ExperimentalTC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine. … TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder).
Dibekacin
go.drugbank.com/drugs/DB13270ApprovedDibekacin is an aminoglycoside antibiotic marketed in Japan [L5623].
Cixutumumab
go.drugbank.com/drugs/DB12250InvestigationalCixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types. … Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Flufenamic acid
go.drugbank.com/drugs/DB02266ApprovedAn anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.
Phenylbutazone
go.drugbank.com/drugs/DB00812ApprovedVet approvedWithdrawnIt is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). … Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)
Synonyms: 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine, 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedioneVatalanib
go.drugbank.com/drugs/DB04879InvestigationalVatalanib is under investigation for the treatment of solid tumors. … Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors.
VLTS-934
go.drugbank.com/drugs/DB05597InvestigationalIt was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease). … VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).
CPG 10101
go.drugbank.com/drugs/DB05530InvestigationalCPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.